Remove 2023 Remove Patients Remove Prescription
article thumbnail

Why script-to-dispense conversion will take centre stage in 2023

pharmaphorum

In 2023, expect manufacturers to further shift their focus away from acquiring new patient prescriptions to retaining existing customers. The account carried an official blue check mark, but in fact it did not belong to the prescription drugmaker. Ensuring patient access. Preventing patient drop-off.

article thumbnail

AbbVie sucks

World of DTC Marketing

The cost of Humira, which is injected via syringe, was more than $72,000 a year on prescription drug websites this week and is not expected to come down until at least 2023. AbbVie significantly inflated prices over the past two decades for patients in the U.S. The executives at AbbVie make over $300 million.

article thumbnail

Bill that would cut down ‘patent thickets’ clears Senate

pharmaphorum

The US Senate has come together to pass a bill that aims to prevent pharma companies from filing multiple patents around biologic drugs as a way to delay biosimilar competitors.Lawmakers unanimously passed the Affordable Prescriptions for Patients Act of 2023 (S-150), which is part of a lengthening list of measures being taken by Congress to curb the (..)

article thumbnail

US companies drive 2023 drug launches positioned for blockbuster success by 2028

Pharmaceutical Technology

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028. Similarly, Almirall S.A.,

Sales 105
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

Ben Locwin will discuss the potential effects of this draft, along with the pharmacological and toxicological considerations for optimizing doses of prescription drugs. Learning Objectives: Dose-response curves and patient treatment: How do pharmacologic and toxicologic principles apply to the dosing of drugs in clinical development?

article thumbnail

7 commercial, sales, and marketing predictions for 2023

pharmaphorum

In 2022, life sciences companies have been hard at work breaking down silos to better serve patients and healthcare professionals (HCPs). And in 2023, these investments will hopefully pay off. Food and Drug Administration’s Office of Prescription Drug Promotion ( OPDP ).”.

article thumbnail

ELITE 2023 Sales MVP Laura Blair of ConnectiveRx

PM360

As the company grew their patient services offerings, Laura has spearheaded the creation of many solutions which have driven sales into hundreds of brands over the last 13 years. Laura has educated the new ConnectiveRx employees on the “real” patient journey. Interestingly, her approach was not only shaped by professional aptitude.

Sales 94